Michael Douglas

TitleHealth Policy Analyst
InstitutionUniversity of California San Francisco
DepartmentClinical Pharmacy
Address3333 Calif. St,Laurel Heights
San Francisco CA 94118
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Featured Publications

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Douglas M, Parker SL, Trosman JR, Slavotinek AM, Phillips KA. Private payer coverage policies for exome sequencing (ES) in pediatric patients: trends over time and analysis of evidence cited. Genet Med. 2018 Jul 12. PMID: 29997388.
      View in: PubMed
    2. Phillips KA, Deverka PA, Hooker GW, Douglas M. Genetic Test Availability And Spending: Where Are We Now? Where Are We Going? Health Aff (Millwood). 2018 May; 37(5):710-716. PMID: 29733704.
      View in: PubMed
    3. Phillips KA, Trosman JR, Deverka PA, Quinn B, Tunis S, Neumann PJ, Chambers JD, Garrison LP, Douglas M, Weldon CB. Insurance coverage for genomic tests. Science. 2018 04 20; 360(6386):278-279. PMID: 29674586.
      View in: PubMed
    4. Christensen KD, Vassy JL, Phillips KA, Blout CL, Azzariti DR, Lu CY, Robinson JO, Lee K, Douglas M, Yeh JM, Machini K, Stout NK, Rehm HL, McGuire AL, Green RC, Dukhovny D. Short-term costs of integrating whole-genome sequencing into primary care and cardiology settings: a pilot randomized trial. Genet Med. 2018 Mar 22. PMID: 29565423.
      View in: PubMed
    5. Marshall DA, Gonzalez JM, Johnson FR, MacDonald KV, Pugh A, Douglas M, Phillips KA. Corrigendum: What are people willing to pay for whole-genome sequencing information, and who decides what they receive? Genet Med. 2018 Jan; 20(1):165. PMID: 29261179.
      View in: PubMed
    6. Chambers JD, Saret CJ, Anderson JE, Deverka PA, Douglas M, Phillips KA. EXAMINING EVIDENCE IN U.S. PAYER COVERAGE POLICIES FOR MULTI-GENE PANELS AND SEQUENCING TESTS. Int J Technol Assess Health Care. 2017 Jan; 33(4):534-540. PMID: 29065945.
      View in: PubMed
    7. Phillips KA, Deverka PA, Trosman JR, Douglas M, Chambers JD, Weldon CB, Dervan AP. Payer coverage policies for multigene tests. Nat Biotechnol. 2017 Jul 12; 35(7):614-617. PMID: 28700544.
      View in: PubMed
    8. Marshall DA, MacDonald KV, Robinson JO, Barcellos LF, Gianfrancesco M, Helm M, McGuire A, Green RC, Douglas M, Goldman MA, Phillips KA. The price of whole-genome sequencing may be decreasing, but who will be sequenced? Per Med. 2017 May; 14(3):203-211. PMID: 28993792.
      View in: PubMed
    9. Phillips KA, Deverka PA, Sox HC, Khoury MJ, Sandy LG, Ginsburg GS, Tunis SR, Orlando LA, Douglas M. Making genomic medicine evidence-based and patient-centered: a structured review and landscape analysis of comparative effectiveness research. Genet Med. 2017 Oct; 19(10):1081-1091. PMID: 28406488.
      View in: PubMed
    10. Trosman JR, Weldon CB, Douglas M, Kurian AW, Kelley RK, Deverka PA, Phillips KA. Payer Coverage for Hereditary Cancer Panels: Barriers, Opportunities, and Implications for the Precision Medicine Initiative. J Natl Compr Canc Netw. 2017 02; 15(2):219-228. PMID: 28188191.
      View in: PubMed
    11. Phillips KA, Douglas M, Trosman JR, Marshall DA. "What Goes Around Comes Around": Lessons Learned from Economic Evaluations of Personalized Medicine Applied to Digital Medicine. Value Health. 2017 01; 20(1):47-53. PMID: 28212968.
      View in: PubMed
    12. Trosman JR, Weldon CB, Douglas M, Deverka PA, Watkins JB, Phillips KA. Decision Making on Medical Innovations in a Changing Health Care Environment: Insights from Accountable Care Organizations and Payers on Personalized Medicine and Other Technologies. Value Health. 2017 01; 20(1):40-46. PMID: 28212967.
      View in: PubMed
    13. Dervan AP, Deverka PA, Trosman JR, Weldon CB, Douglas M, Phillips KA. Payer decision making for next-generation sequencing-based genetic tests: insights from cell-free DNA prenatal screening. Genet Med. 2017 05; 19(5):559-567. PMID: 27657682.
      View in: PubMed
    14. Marshall DA, Gonzalez JM, Johnson FR, MacDonald KV, Pugh A, Douglas M, Phillips KA. What are people willing to pay for whole-genome sequencing information, and who decides what they receive? Genet Med. 2016 12; 18(12):1295-1302. PMID: 27253734.
      View in: PubMed
    15. Clain E, Trosman JR, Douglas M, Weldon CB, Phillips KA. Availability and payer coverage of BRCA1/2 tests and gene panels. Nat Biotechnol. 2015 Sep; 33(9):900-2. PMID: 26348951; PMCID: PMC4625918.
    16. Douglas M, Ladabaum U, Pletcher MJ, Marshall DA, Phillips KA. Economic evidence on identifying clinically actionable findings with whole-genome sequencing: a scoping review. Genet Med. 2016 Feb; 18(2):111-6. PMID: 25996638; PMCID: PMC4654986.
    17. Phillips KA, Ladabaum U, Pletcher MJ, Marshall DA, Douglas M. Key emerging themes for assessing the cost-effectiveness of reporting incidental findings. Genet Med. 2015 Apr; 17(4):314-5. PMID: 25835195; PMCID: PMC4395812.
    18. Garfeld S, Douglas M, MacDonald KV, Marshall DA, Phillips KA. Consumer familiarity, perspectives and expected value of personalized medicine with a focus on applications in oncology. Per Med. 2015 Jan 01; 12(1):13-22. PMID: 25620993.
      View in: PubMed
    19. Phillips KA, Trosman JR, Kelley RK, Pletcher MJ, Douglas M, Weldon CB. Genomic sequencing: assessing the health care system, policy, and big-data implications. Health Aff (Millwood). 2014 Jul; 33(7):1246-53. PMID: 25006153; PMCID: PMC4113721.
    20. Dotson WD, Douglas M, Kolor K, Stewart AC, Bowen MS, Gwinn M, Wulf A, Anders HM, Chang CQ, Clyne M, Lam TK, Schully SD, Marrone M, Feero WG, Khoury MJ. Prioritizing genomic applications for action by level of evidence: a horizon-scanning method. Clin Pharmacol Ther. 2014 Apr; 95(4):394-402. PMID: 24398597; PMCID: PMC4689130.
    21. Clyne M, Schully SD, Dotson WD, Douglas M, Gwinn M, Kolor K, Wulf A, Bowen MS, Khoury MJ. Horizon scanning for translational genomic research beyond bench to bedside. Genet Med. 2014 Jul; 16(7):535-8. PMID: 24406461.
      View in: PubMed
    22. Phillips KA, Ann Sakowski J, Trosman J, Douglas M, Liang SY, Neumann P. The economic value of personalized medicine tests: what we know and what we need to know. Genet Med. 2014 Mar; 16(3):251-7. PMID: 24232413; PMCID: PMC3949119.
    23. Palomaki GE, Melillo S, Marrone M, Douglas M. Use of genomic panels to determine risk of developing type 2 diabetes in the general population: a targeted evidence-based review. Genet Med. 2013 Aug; 15(8):600-11. PMID: 23492876; PMCID: PMC4684162.
    24. Palomaki GE, Melillo S, Neveux L, Douglas M, Dotson WD, Janssens AC, Balkite EA, Bradley LA. Use of genomic profiling to assess risk for cardiovascular disease and identify individualized prevention strategies--a targeted evidence-based review. Genet Med. 2010 Dec; 12(12):772-84. PMID: 21045709.
      View in: PubMed
    25. Teutsch SM, Bradley LA, Palomaki GE, Haddow JE, Piper M, Calonge N, Dotson WD, Douglas M, Berg AO. The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP Working Group. Genet Med. 2009 Jan; 11(1):3-14. PMID: 18813139; PMCID: PMC2743609.
    26. Palomaki GE, Bradley LA, Douglas M, Kolor K, Dotson WD. Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review. Genet Med. 2009 Jan; 11(1):21-34. PMID: 19125129; PMCID: PMC2743611.
    27. Schinsky MF, Morey RE, Steigerwalt AG, Douglas M, Wilson RW, Floyd MM, Butler WR, Daneshvar MI, Brown-Elliott BA, Wallace RJ, McNeil MM, Brenner DJ, Brown JM. Taxonomic variation in the Mycobacterium fortuitum third biovariant complex: description of Mycobacterium boenickei sp. nov., Mycobacterium houstonense sp. nov., Mycobacterium neworleansense sp. nov. and Mycobacterium brisbanense sp. nov. and recognition of Mycobacterium porcinum from human clinical isolates. Int J Syst Evol Microbiol. 2004 Sep; 54(Pt 5):1653-67. PMID: 15388725.
      View in: PubMed
    28. Daneshvar MI, Hollis DG, Weyant RS, Steigerwalt AG, Whitney AM, Douglas M, Macgregor JP, Jordan JG, Mayer LW, Rassouli SM, Barchet W, Munro C, Shuttleworth L, Bernard K. Paracoccus yeeii sp. nov. (formerly CDC group EO-2), a novel bacterial species associated with human infection. J Clin Microbiol. 2003 Mar; 41(3):1289-94. PMID: 12624070; PMCID: PMC150304.
    29. Daneshvar MI, Douglas M, Weyant RS. Cellular fatty acid composition of Lautropia mirabilis. J Clin Microbiol. 2001 Nov; 39(11):4160-2. PMID: 11682548; PMCID: PMC88505.
    30. Teixeira LM, Carvalho MG, Espinola MM, Steigerwalt AG, Douglas M, Brenner DJ, Facklam RR. Enterococcus porcinus sp. nov. and Enterococcus ratti sp. nov., associated with enteric disorders in animals. Int J Syst Evol Microbiol. 2001 Sep; 51(Pt 5):1737-43. PMID: 11594604.
      View in: PubMed
    31. Daneshvar MI, Hollis DG, Steigerwalt AG, Whitney AM, Spangler L, Douglas M, Jordan JG, MacGregor JP, Hill BC, Tenover FC, Brenner DJ, Weyant RS. Assignment of CDC weak oxidizer group 2 (WO-2) to the genus Pandoraea and characterization of three new Pandoraea genomospecies. J Clin Microbiol. 2001 May; 39(5):1819-26. PMID: 11325997; PMCID: PMC88032.
    32. Douglas M, Rogers SO. DNA damage caused by common cytological fixatives. Mutat Res. 1998 Jun 05; 401(1-2):77-88. PMID: 9639679.
      View in: PubMed